DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Orthofix

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Orthofix Medical Inc. due to significant losses suffered by investors following the termination of key executives and the subsequent decline in stock price [1][3][4]. Group 1: Company Overview - Orthofix Medical Inc. is publicly traded on NASDAQ under the ticker OFIX [1]. - The company recently faced a major leadership change, with the termination of its CEO, CFO, and Chief Legal Officer for cause due to violations of the company's code of conduct [4]. Group 2: Legal Actions and Investor Impact - Investors who incurred losses exceeding $75,000 between October 11, 2022, and September 12, 2023, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1]. - Following the announcement of executive terminations, Orthofix's stock price dropped by $5.62, or 30.2%, closing at $13.01 per share, indicating a significant impact on investor value [4]. - A federal securities class action has been filed against Orthofix, with a deadline of October 21, 2024, for investors to seek the role of lead plaintiff [1][5]. Group 3: Investigation and Whistleblower Encouragement - The investigation by Faruqi & Faruqi seeks information regarding Orthofix's conduct, inviting whistleblowers, former employees, and shareholders to come forward [6].